Journal of Applied Biological Chemistry

The Korean Society for Applied Biological Chemistry (한국응용생명화학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibitory effects of artemether on collagen-induced platelet aggregation via regulation of phosphoprotein inducing PI3K/Akt and MAPK

  • Received : 2022.07.01
  • Accepted : 2022.08.05
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Pathophysiological reaction of platelets in the blood vessel is an indispensable part of thrombosis and cardiovascular disease, which is the most common cause of death in the world. In this study, we performed in vitro assays to evaluate antiplatelet activity of artemether in human platelets and attempted to identify the mechanism responsible for protein phosphorylation. Artemether is a derivative of artemisinin, known as an active ingredient of Artemisia annua, which has been reported to be effective in treating malaria, and is known to function through antioxidant and metabolic enzyme inhibition. However, the role of artemether in platelet activation and aggregation and the mechanism of action of artemether in collagen-induced human platelets are not known until now. In this study, the effect of artesunate on collagen-induced human platelet aggregation was confirmed and the mechanism of action of artemether was clarified. Artemether inhibited the phosphorylation of PI3K/Akt and Mitogen-activated protein kinases, which are phosphoproteins that are known to act in the signal transduction process when platelets are activated. In addition, artemether decreased TXA2 production and decreased granule secretion in platelets such as ATP and serotonin release. As a result, artemether strongly inhibited platelet aggregation induced by collagen, a strong aggregation inducer secreted from vascular endothelial cells, with an IC50 of 157.92 μM. These results suggest that artemether has value as an effective antithrombotic agent for inhibiting the activation and aggregation of human platelets through vascular injury.

Keywords

References

  1. Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, Soliman MA, Frohlich B, Mininberg DT, Monge JM, Vallodolid CM, Cox SL, el-Maksoud GA, Badr I, Miyamoto MI, el-Din AeH, Narula J, Finch CE, Thomas GS (2013) Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet 381: 1211-1222. doi: 10.1016/S0140-6736(13)60598-X
  2. Rouzer CA, Marnett LJ (2005) Structural and functional differences between cyclooxygenases: fatty acid oxygenases with a critical role in cell signaling. Biochem Biophys Res Commun 338: 34-44. doi:10.1016/j.bbrc.2005.07.198
  3. Li Z, Delaney MK, O'Brien KA, Du X (2010) Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30: 2341-2349. doi: 10.1161/ATVBAHA.110.207522
  4. Guidetti GF, Canobbio I, Torti M (2015) PI3K/Akt in platelet integrin signaling and implications in thrombosis. Adv Biol Regul 59: 36-52. doi: 10.1016/j.jbior.2015.06.001
  5. Aslan JE, Tormoen GW, Loren CP, Pang J, McCarty OJT (2011) S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood 118: 3129-3136. doi: 10.1182/blood-2011-02-331579
  6. Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, Davis RJ, Rosa J, Bryckaert M (2010) Platelet JNK1 is involved in secretion and thrombus formation. Blood 115: 4083-4092. doi: 10.1182/blood-2009-07-233932
  7. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 113: 893-901. doi: 10.1182/blood-2008-05-155978
  8. O'Brien KA, Stojanovic-Terpo A, Hay N, Du X (2011) An important role for Akt3 in platelet activation and thrombosis. Blood 118: 4215-4223. doi: 10.1182/blood-2010-12-323204
  9. Yin H, Stojanovic A, Hay N, Du X (2008) The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood 111: 658-665. doi: 10.1182/blood-2007-04-085514
  10. Esu EB, Effa EE, Opie ON, Meremikwu MM (2019) Artemether for severe malaria, Cochrane. Database. Syst Rev 6: CD010678. doi:10.1002/14651858.CD010678.pub3
  11. Saeed ME, Krishna S, Greten HJ, Kremsner PG, Efferth T (2016) Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacological Research 110: 216-226. doi: 10.1016/j.phrs.2016.02.017
  12. Chuang WY, Kung PH, Kuo CY, Wu CC (2013) Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway. Thromb Haemost 109: 1120-1130. doi: 10.1160/ TH12-09-0636
  13. Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330: 1287-1294. doi: 10.1056/NEJM199405053301808
  14. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 113: 893-901. doi: 10.1182/blood-2008-05-155978
  15. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M (1999) Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94: 3800-3805. doi: 10.1182/blood.V94.11.3800
  16. Kramer RM, Roberts EF, Strifler BA, Johnstone EM (1995) Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 270: 27395-27398. doi: 10.1074/jbc.270.46.27395
  17. Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M (2002) Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 531: 475-482. doi: 10.1016/S0014-5793(02)03587-1
  18. Chang MC, Wang TM, Yeung SY, Jeng PY, Liao CH, Lin CC, Lin BR, Jeng JH (2011) Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis 219: 559-565. doi: 10.1016/j.atherosclerosis.2011.09.031
  19. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96: 1109-1116. doi:10.1161/01.CIR.96.4.1109
  20. Patrono C (2001) Aspirin: new cardiovascular uses for an old drug. Am J Med 110: 62S-65S. doi: 10.1016/S0002-9343(00)00645-8
  21. Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ (1996) p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271: 27723-27729. doi: 10.1074/jbc.271.44.27723
  22. McNicol A, Shibou TS (1998) Translocation and phosphorylation of cytosolic phospholipase A2 in activated platelets. Thromb Res 92: 19-26. doi: 10.1016/S0049-3848(98)00097-8
  23. Calderwood DA (2004) Integrin activation. J Cell Sci 117: 657-666. doi:10.1242/jcs.0101